|Bid||40.00 x 800|
|Ask||42.20 x 1000|
|Day's Range||41.72 - 45.50|
|52 Week Range||40.25 - 136.90|
|Beta (3Y Monthly)||1.01|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||83.25|
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, November 1, 2018 following release of its third quarter 2018 financial results. Please dial in at least ten minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at http://www.pumabiotechnology.com. A replay of the call will be available approximately one hour after completion of the call and will be archived on Puma’s website for 90 days.
Puma Biotech (PBYI) focuses on improving sales of its flagship and the only approved product Nerlynx. The drug's label expansion programs also appear promising.
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Celcuity Inc. (CELC), a functional cellular analysis company that is discovering new cancer subtypes and commercializing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, today announced a clinical trial agreement with Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, and West Cancer Center, to conduct a Phase II clinical trial. This open-label Phase II trial will evaluate the efficacy and safety of Puma’s drug, NERLYNX ®(neratinib), and chemotherapy in up to 27 early stage triple-negative breast cancer patients selected with Celcuity’s CELx HER2 Signaling Function (“CELx HSF”) Test. Under this agreement, West Cancer Center will serve as the sponsor and principal investigator of the trial and is responsible for enrolling patients and managing clinical data.
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that on October 9, 2018, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 18,750 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017, and provides for the granting of equity awards to new employees of Puma. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology, Inc. has been advised that its licensing partner CANbridge Pharmaceutical Inc received confirmation that China’s National Medical Products Administration has accepted its New Drug Application for NERLYNX® for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab based-therapy.
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 1:10 p.m.
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that on September 5, 2018 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 31,125 shares of Puma common stock to four new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
Puma Biotech (PBYI) gains EU approval for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.
The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals
Drug approvals in Europe and other pipeline updates comprise some of the key developments in the biotech sector this week.
On September 4, the European Commission approved the marketing authorization of Puma Biotechnology’s Nerlynx as extended adjuvant therapy for the treatment of adults with early-stage HER2-positive (hormone receptor-2 positive) breast cancer who completed previous adjuvant trastuzumab-containing therapy less than a year ago.
Roche’s (RHHBY) Herceptin reported revenues of 3.6 billion Swiss francs in the first half compared to 3.5 billion Swiss francs in the first half of 2017, reflecting ~2.0% YoY year-over-year growth at CER (constant exchange rates).
NEW YORK, Aug. 23, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Patterson-UTI ...
In June, the Committee for Medicinal Products for Human Use recommended a favorable opinion on the approval of Puma Biotechnology’s (PBYI) Nerlynx for its commercialization in the European Union for the prolonged adjuvant therapy of adults with early-stage HER2+ (hormone-receptor-positive) breast cancer whose prior adjuvant trastuzumab-based therapy is less than one year from completion.
Puma Biotechnology (PBYI) released its second-quarter earnings results on August 9. It reported net revenue of $117.3 million in the first half of 2018. Puma Biotechnology’s revenue came primarily from its sales of Nerlynx.
Puma Biotech (PBYI) posts narrower-than-estimated loss in Q2. Also, rapid growth of its only marketed drug, Nerlynx, boosts sales.
NEW YORK, NY / ACCESSWIRE / August 10, 2018 / U.S. markets finished mostly lower on Thursday, as broader market was dragged lower by weak performance from the industrial and energy sector matched with ...
Puma Biotech (PBYI) delivered earnings and revenue surprises of 53.17% and 0.77%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Los Angeles-based company said it had a loss of $1.17 per share. Losses, adjusted for stock option expense, came to 59 cents per share. The biopharmaceutical company posted revenue of $50.8 million ...
Shares of Puma Biotechnology Inc. (pbyi) rose more than 19% in the extended session Thursday after the company reported a narrower-than-expected quarterly loss and sales came in above forecasts. Puma said it lost $44.3 million, or $1.17 a share, in the second quarter, compared with a net loss of $77.8 million, or $2.10 a share, in the year-ago period. Puma in July got approval from the U.S. Food and Drug Administration for Nerlynx, used in the treatment of breast cancer, and the company began shipment to wholesalers at the end of that month.
Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2018. Unless otherwise stated, all comparisons are for the second quarter 2018 compared to the second quarter 2017.
On Puma Biotechnology's (PBYI) second-quarter 2018 earnings call, investor focus will be on the sales figures of its only marketed drug Nerlynx.